Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice

Neurobiology of Disease

Volumn 38, Issue 1, 2010, Pages 27-35

  Machová, Eva ^a   Rudajev, Vladimír ^a   Smyčková, Helena ^a   Koivisto, Henna ^b   Tanila, Heikki ^b,c   Doležal, Vladimír ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Acetylcholine release; Alzheimer's disease; Brain cortex; G proteins; Hippocampus; Muscarinic neurotransmission; Striatum; Transgenic APPswe PS1dE9 mice

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PRESENILIN 1;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; BRAIN CORTEX; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HIPPOCAMPUS; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACETYLCHOLINE; AGE FACTORS; AGING; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BRAIN CHEMISTRY; CEREBRAL CORTEX; CHOLINERGIC AGONISTS; CHOLINERGIC FIBERS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GTP-BINDING PROTEINS; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; ORGAN CULTURE TECHNIQUES; PRESENILIN-1; RECEPTORS, MUSCARINIC;

EID: 77549087116     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.12.023     Document Type: Article

References (43)

1. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163 (2000) 495-529
2. Bartus R.T., Dean R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
3. Bowen D.M., Smith C.B., White P., and Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99 (1976) 459-496
4. Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., and Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10075-10078
5. Bymaster F.P., McKinzie D.L., Felder C.C., and Wess J. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 28 (2003) 437-442
6. Davies P., and Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403
7. Doležal V., and Kašparová J. Beta-amyloid and cholinergic neurons. Neurochem. Res. 28 (2003) 499-506
8. Doležal V., and Tuček S. Positive and negative effects of tacrine (tetrahydroaminoacridine) and methoxytacrine on the metabolism of acetylcholine in brain cortical prisms incubated under "resting" conditions. J. Neurochem. 56 (1991) 1207-1215
9. 3H-acetylcholine release from rat striatum by muscarinic receptor agonists. Br. J. Pharmacol. 124 (1998) 1213-1218
10. Doležal V., and Wecker L. Modulation of acetylcholine release from rat striatal slices: interaction between 4-aminopyridine and atropine. J. Pharmacol. Exp. Ther. 258 (1991) 762-766
11. Doležal V., Jackisch R., Hertting G., and Allgaier C. Activation of dopamine D1 receptors does not affect D2 receptor-mediated inhibition of acetylcholine release in rabbit striatum. Naunyn Schmiedebergs Arch. Pharmacol. 345 (1992) 16-20
12. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., Neary D., Snowden J.S., and Wilcock G.K. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N. Engl. J. Med. 313 (1985) 7-11
13. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66 (1999) 137-147
14. Goto Y., Niidome T., Hongo H., Akaike A., Kihara T., and Sugimoto H. Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Eur. J. Pharmacol. 583 (2008) 84-91
15. Haass C., and Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders?. Nat. Neurosci. 4 (2001) 859-860
16. Jakubík J., El-Fakahany E.E., and Doležal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M1 and M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 70 (2006) 656-666
17. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., and Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13 (2004) 159-170
18. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
19. Lazareno S., Doležal V., Popham A., and Birdsall N.J. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65 (2004) 257-266
20. Liu Y., Yoo M.-J., Savonenko A., Stirling W., Price D.L., Borchelt D.R., Mamounas L., Lyons W.E., Blue M.E., and Lee K.K. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 28 51 (2008) 1385-13814
21. Machová E., Jakubík J., El-Fakahany E.E., and Doležal V. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain. J. Pharmacol. Exp. Ther. 322 (2007) 316-323
22. Machová E., Jakubík J., Michal P., Oksman M., Iivonen H., Tanila H., and Doležal V. Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice. Neurobiol. Aging 29 (2008) 368-378
23. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 145 (2004) 67-78
24. Mesulam M.M., Mufson E.J., Wainer B.H., and Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10 (1983) 1185-1201
25. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., and Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J. Neurochem. 105 (2008) 584-594
26. Nitsch R.M., Slack B.E., Wurtman R.J., and Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (1992) 304-307
27. Perez S.E., Lazarov O., Koprich J.B., Chen E.Y., Rodriguez-Menendez V., Lipton J.W., Sisodia S.S., and Mufson E.J. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J. Neurosci. 25 (2005) 10220-10229
28. Perry E.K., Gibson P.H., Blessed G., Perry R.H., and Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci. 34 (1977) 247-265
29. Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1 (1977) 189
30. Perry E.K., Kilford L., Lees A.J., Burn D.J., and Perry R.H. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann. Neurol. 54 (2003) 235-238
31. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83 (1977) 346-356
32. Raiteri M. Functional pharmacology in human brain. Pharmacol. Rev. 58 2 (2006) 162-193
33. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., and Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18 (2005) 602-617
34. Savonenko A.V., Xu G.M., Price D.L., Borchelt D.R., and Markowska A.L. Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol. Dis. 12 (2003) 194-211
35. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
36. Shemer I., Holmgren C., Min R., Fulop L., Zilberter M., Sousa K.M., Farkas T., Hartig W., Penke B., Burnashev N., Tanila H., Zilberter Y., and Harkany T. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur. J. Neurosci. 23 (2006) 2035-2047
37. Sims N.R., Bowen D.M., Smith C.C., Flack R.H., Davison A.N., Snowden J.S., and Neary D. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1 (1980) 333-336
38. Sims N.R., Bowen D.M., and Davison A.N. [14C]acetylcholine synthesis and carbon 14C dioxide production from [U- 14C]glucose by tissue prisms from human neocortex. Biochem. J. 196 (1981) 867-876
39. Snowdon D.A. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 139 (2003) 450-454
40. Starke K. Presynaptic alpha-autoreceptors. Rev. Physiol. Biochem. Pharmacol. 107 (1987) 73-146
41. Tsang S.W., Lai M.K., Kirvell S., Francis P.T., Esiri M.M., Hope T., Chen C.P., and Wong P.T. Impaired coupling of muscarinic M(1) receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol. Aging 27 (2005) 1216-1223
42. Tzavara E.T., Bymaster F.P., Felder C.C., Wade M., Gomeza J., Wess J., McKinzie D.L., and Nomikos G.G. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol. Psychiatry 8 (2003) 673-679
43. Zhang W., Basile A.S., Gomeza J., Volpicelli L.A., Levey A.I., and Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J. Neurosci. 22 (2002) 1709-1717